Harms: pulmonary embolus or DVT · adults with or without existing CVD
It is very uncertain whether high changes harms: pulmonary embolus or DVT compared with low long‐chain omega‐3 fats (very low certainty).
1 finding from 1 review
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole may leads to higher clearance or reduction of antibody titres (N) (a) at 12 months (b)… compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
It is very uncertain whether benznidazole changes clearance of parasitaemia demonstrated by negative xenodiagnosis,… compared with placebo (very low certainty).
1 finding from 1 review
Pathological demonstration of tissue parasites (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (N) (a) Heart failure (b) Sustained ventricular tachycardia · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole showed no clear difference in clinical improvement (N) (a) Heart failure (b) Sustained ventricular… compared with placebo (low certainty).
1 finding from 1 review
Quality of life · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole probably leads to higher adverse events (N) compared with placebo (moderate certainty).
1 finding from 1 review
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
It is very uncertain whether nifurtimox changes clearance or reduction of antibody titres (N) compared with placebo (very low certainty).
1 finding from 1 review
Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pathological demonstration of tissue parasites (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival (risk of death) ‐ adults with myocarditis, median · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ adults with myocarditis, median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Side effects ‐ mild infusion effects, 12‐month · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes side effects ‐ mild infusion effects, 12‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival (risk of death) ‐ children with myocarditis, 6‐month · children with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ children with myocarditis, 6‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Short‐term impact (< 12 months) child vegetable intake · children aged 5 years and under
1 finding from 1 review
Short‐term impact (< 12 months) child fruit and vegetable intake · children aged 5 years and under
1 finding from 1 review
Cost or cost effectiveness ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found